1. Home
  2. EDSA vs RMCO Comparison

EDSA vs RMCO Comparison

Compare EDSA & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • RMCO
  • Stock Information
  • Founded
  • EDSA 2015
  • RMCO 2021
  • Country
  • EDSA Canada
  • RMCO United States
  • Employees
  • EDSA N/A
  • RMCO N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • RMCO Multi-Sector Companies
  • Sector
  • EDSA Health Care
  • RMCO Miscellaneous
  • Exchange
  • EDSA Nasdaq
  • RMCO Nasdaq
  • Market Cap
  • EDSA 17.2M
  • RMCO 14.9M
  • IPO Year
  • EDSA N/A
  • RMCO N/A
  • Fundamental
  • Price
  • EDSA $2.39
  • RMCO $1.97
  • Analyst Decision
  • EDSA Strong Buy
  • RMCO
  • Analyst Count
  • EDSA 2
  • RMCO 0
  • Target Price
  • EDSA $13.00
  • RMCO N/A
  • AVG Volume (30 Days)
  • EDSA 11.7K
  • RMCO 106.7K
  • Earning Date
  • EDSA 08-08-2025
  • RMCO 11-14-2025
  • Dividend Yield
  • EDSA N/A
  • RMCO 0.26%
  • EPS Growth
  • EDSA N/A
  • RMCO N/A
  • EPS
  • EDSA N/A
  • RMCO N/A
  • Revenue
  • EDSA N/A
  • RMCO $2,641,171.00
  • Revenue This Year
  • EDSA N/A
  • RMCO N/A
  • Revenue Next Year
  • EDSA N/A
  • RMCO N/A
  • P/E Ratio
  • EDSA N/A
  • RMCO N/A
  • Revenue Growth
  • EDSA N/A
  • RMCO 292.46
  • 52 Week Low
  • EDSA $1.55
  • RMCO $0.85
  • 52 Week High
  • EDSA $5.00
  • RMCO $2.34
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 51.55
  • RMCO 57.53
  • Support Level
  • EDSA $2.41
  • RMCO $1.83
  • Resistance Level
  • EDSA $2.47
  • RMCO $2.00
  • Average True Range (ATR)
  • EDSA 0.09
  • RMCO 0.15
  • MACD
  • EDSA -0.01
  • RMCO -0.02
  • Stochastic Oscillator
  • EDSA 48.15
  • RMCO 27.45

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About RMCO Royalty Management Holding Corporation

Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

Share on Social Networks: